Condition: Smokers · Chronic Obstructive Pulmonary Disease · Sponsor: Assistance Publique - Hôpitaux de Paris
Chronic Obstructive Pulmonary Disease (COPD), , secondary to smoking, is a major public health issue with very high direct and indirect costs. The impact on the health system of undiagnosed patients, up to 70% of patients, is increasingly documented. However, systematic spirometry screening remains controversial among smokers in the absence of data to link the detection of new patients with improved management and clinical events and health goals. More generally, there is little data on the evolution of patients in real life once they have entered the care system. The premise is that with systematic screening in general medicine, it is possible to identify the evolution of newly diagnosed COPD patients, to distinguish the different possible evolutions according to the initial phenotype and the management.
This description comes directly from the study's public registry record.
Laurent BOYER, MD · (0) 1 49 81 26 90 · laurent.boyer@aphp.fr
Lila KACI · (0) 1 49 81 36 24 · lila.kaci@aphp.fr
Always discuss trial participation with your own doctor first.
| Hopital Henri MONDOR | Créteil, Île-de-France Region, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04252781